SERVICES

临床Trials

让我们的合作伙伴提供成规,innovative solutions that redefine the possibility of drug development. Learn how to accelerate patient recruitment and optimize protocol design while reducing patient burden and increasing retention.

Trending Topics

image of a smartphone

临床试验的转化方法

LabCorp Transforms the Clinical Trial Experience to Streamline its Drug Development Process

Company goes beyond decentralized clinical trials to deliver seamless tech-enabled, patient-centric enterprise solutions. LabCorp now offers a comprehensive and fully integrated patient, site, and customer experience for DCTs.

Blog

病人智力:在Covid-19时代设计临床试验

在Covid-19时代,患者不能等待新的疫苗和疗法来到市场。这就是为什么即使在这些挑战时期,Covance也被重点关注,而不是以往任何时候都在理解患者对临床试验参与的看法。随着社会疏散已成为新的正常情况,在制定议定书时,应考虑到解与审判参与有关的偏好变更的必要性。

网络研讨会

Covid-19(冠状病毒)大流行期间的纳什临床发展

Covid-19大流行在临床发展中引起了前所未有的挑战。旅行限制,社会疏散和对疾病的恐惧正在阻碍常规试验行为。通常,常规患者和监测对医疗保健设施的监测访问现在是例外,研究协调员和现场工作人员对他们的时间提高了需求,并且在某些情况下,裁员已经使某些网站无法像往常一样继续持续。为了帮助保持患者安全并允许审判进步,全球监管机构已发出工业,调查员和机构审查委员会的指导。亚博全站官网

News

LabCorp Accelerates Adoption of Decentralized Clinical Trials, Expands Technology Ecosystem Through Alliance with Medable

Labcorp是一家领先的全球生命科学公司,这是一家深受综合的引导患者护理,今天宣布其药物开发业务,正在扩大其技术生态系统,加速通过分散的临床试验,通常被称为杂种和虚拟临床试验。Covance正在通过与可卧台的联盟扩展其分散的试验技术生态系统,这是一种用于数字临床试验的领先的软件提供商。

By the Numbers

3,800 学习
64,000 Investigator Studies
660,000 Patients

Covance Clinical Development Services activity during the last 5 years.

一个景气科学家的照片在实验室里

Featured Article

Decentralized Clinical Trials – Best Practices for Designing a Flexible, Resilient Protocol

As drug development sponsors are incorporating patient-centric elements into their traditional clinical trial designs, there are several factors to consider during the study planning phase. Whether using telemedicine, mobile nursing services, laboratory support, patient service centers, investigational product management or a combination of these elements, it is important to develop an operational strategy that allows for flexibility and accounts for complete oversight of each connection point between patients, service providers and the sponsor.

Have Questions?

  • 什么是FSP?

    FSP代表功能服务提供商,是关于提供定制的全局解决方案,使客户能够有效地管理其临床试验组合。这包括提出质量人员,智能流程和深度技术专业知识,以直接在客户的业务上工作。越来越多的制药和生物技术公司正在转向该模型以减少其开销,并使其运营更加壮大,更高效。CovanceFSPX®是功能服务提供商,您可以通过强大的协作和质量承诺来提供可自定义的解决方案。Learn more about FSP

  • What are Decentralized Clinical Trials, Virtual Clinical and Hybrid Clinical Trials?

    The need to transition from a site-centric approach to a more patient-centric clinical trial model led to innovations that reduce patient burden by reducing the amount of travel needed, allowing more services to be performed at or near the patients’ homes and incorporate new ways of identifying and enrolling trial participants. First called “virtual trials,” meaning investigator sites would play little role, the industry rapidly learned that most trials would involve a hybrid approach, including both traditional and novel technologies. Now this spectrum of trials is usually termed “Decentralized Clinical Trials” or DCT for short. We deliver a patient-centric ecosystem of conveniently located resources all connected by a single technology platform. An example of a DCT model is our solution that includes connecting LabCorp’s U.S.-based Patient Service Centers, global partnerships with reputable retail pharmacies, as well as home health phlebotomy and nursing service providers, with a best-in-class technology platform. We can pair site-based patient recruitment with web-based direct-to-patient outreach.Learn more about DCTs

  • When should Phase IV trials be considered for drug development?

    第IV阶段试验在现实世界中进行“。因此,它们可以补充,在某些情况下更换III阶段试验。如果您的药物用于罕见/孤儿指示,则终原疾病或其中III期试验认为是不道德的,则IV期试验可能对调节剂是优选的。对于晚期细胞和基因治疗,应考虑第IV期试验和随附的长期随访研究。Learn more about Phase IV trials

  • How can Phase IV studies/trials, and Phase IIIb trials be combined to explore new indications?

    探索新的previ迹象ously approved products requires an appropriate level of safety and efficacy data to be collected to satisfy regulators. Depending upon the target indication, a Phase IV study may suffice to generate the real-world evidence (RWE) needed. However, where more thorough investigation is required, a Phase IIIb clinical trial or a Phase IV trial may be required. Our aim is to maximize efficiency by working with you to determine the most appropriate approach for your product and target indication.

  • How does Covance utilize proprietary data to improve clinical study outcomes?
    • Only Covance combines one of the world’s largest sources of de-identified lab results and patient intelligence data with investigator data from the majority of global clinical trials that provide insights to increase efficiencies and effectiveness in clinical drug development.
    • LabCorp Data – using LabCorp’s real-world, de-identified clinical laboratory data on over 150 million patients, we can assess populations who meet your protocol’s eligibility criteria and accurately model the impact that the protocol inclusion/exclusion criteria will have on the patient pool size.
    • Covance Central Labs Data – Covance generates more clinical trial data than anyone else in the world. Our global proprietary data helps us predict future investigator performance and capacity to run multiple studies.
    • Patient Direct – we have access to ~150 million patients and have a rapidly growing database of people who have given us permission to reach out directly to them for participation in clinical studies.Learn more
  • What is the Covance Integrated Clinical Pharmacology Solution?

    药物开发是一个复杂的和具有挑战性的路径way to navigate. In today’s environment with ever more complex drugs and drug targets, it is essential to think beyond the four walls of a traditional clinical pharmacology unit in order to optimize early clinical development. An integrated development platform, including the resources, experience, expertise and infrastructure necessary to design and execute early clinical studies is an effective way of mitigating risk. A multidisciplinary team that understands the market and the molecule can devise a regulatory strategy and an early clinical development plan that aims to efficiently determine whether or not a drug candidate should continue to be developed. Effective use of the integrated platform allows for efficient determination of whether or not the drug achieves sufficient levels in the relevant physiologic compartment, whether it interacts with its intended target as anticipated and whether it has any unanticipated or otherwise untoward biological effects. Increasingly, this requires not only strong clinical pharmacology expertise, but also access to biomarker testing and project management staff that can guide a protocol seamlessly from cohorts of normal healthy volunteers in a clinical pharmacology unit to cohorts of patients at multiple investigative sites.Learn more about clinical pharmacology

Covance Insights.

How the RACE for Children Act Impacts Pediatric Oncology Drug Development
How the RACE for Children Act Impacts Pediatric Oncology Drug Development
Videos & WebinarsPlay Video
View this webinar to get insights spanning rare diseases, regulatory strategy, oncology and pediatric drug development. Find out about the current pediatric oncology drug development landscape and an industry-focused view of applicable regulations and the RACE for Children Act.
Read More
Mobile Health and Hybrid/Virtual Trials in Diabetes
Mobile Health and Hybrid/Virtual Trials in Diabetes
Videos & WebinarsPlay Video
The management landscape for Diabetes Mellitus (both Type 1 and Type 2) has changed drastically. Innovations in the mobile health technology space have allowed patients with diabetes to have improved glycemic control with more data available to them and their providers. Clinical trials in diabetes have also improved data capture, safety and accessibility using new mobile health platforms, specifically hybrid and virtual trial technology. This educational webinar will provide an overview of the mobile health technology space, highlighting current innovations and challenges. The discussion will be moderated by Dr. Barry Goldstein following presentations by Dr. Manasi Jaiman and Dr. Bola Oyegunwa.
Read More
Inflammatory Bowel Disease clinical studies and the importance of patient centricity
Inflammatory Bowel Disease clinical studies and the importance of patient centricity
博客
In today's exceptionally crowded clinical trial environment of inflammatory bowel disease (IBD), patient-centric practices can help your study of Crohn's disease (CD) or ulcerative colitis (UC) stand out to both patients and sites. Learn about your options to increase your trial's patient centricity, encourage recruitment and promote ongoing patient retention.
Read More
解决制药和生物技术公司数据管理的挑战:介绍实验室FSPX
解决制药和生物技术公司数据管理的挑战:介绍实验室FSPX
博客
确保临床试验记录的过程是准确的,在实验室和临床资料来源之间准确,完全和解,这可能是当今制药和生物技术公司的挫折感。无论数据是否来自合同研究组织(CRO),中央实验室或第三方实验室,需要根据独特的赞助商格式/行业需求及时提供清洁数据的需求变得非常复杂。
Read More

Subscribe now

Stay up to date with the latest news from Covance

Learn More